Harvard University - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH4742D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

September 2018

Total pages

100

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

Harvard University (Harvard) is an educational and research university that offers undergraduate and post graduate programs. The university offers courses such as accounting and management, anthropology, epidemiology, mathematics, music, pathology, psychology, sociology, visual and environmental studies, women's studies in religion, physics. It provides courses such as pediatric dentistry; landscape, architecture, and urban planning; biological chemistry and molecular pharmacology; comparative literature and microbiology and molecular genetics. Harvard offers libraries, museums, laboratories and research centers to support scholarly work. The university collaborates with other universities and research institutions for its research activities. It operates through various schools and colleges. Harvard is headquartered in Cambridge, Massachusetts, the US.

Harvard University-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

Harvard University, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Harvard University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Harvard University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Harvard University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Harvard University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Harvard University, Medical Devices Deals, 2012 to YTD 2018 12

Harvard University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Harvard University, Pharmaceuticals & Healthcare, Deal Details 17

Partnerships 17

Beam Therapeutics Enters into Licensing Agreement with Harvard University 17

Bristol-Myers Squibb Enters into Research Agreement with Harvard Stem Cell Institute 18

Frequency Therapeutics Enters into Agreement with Harvard University and US Army Institute of Surgical Research 19

Les Laboratoires Servier Enters into Agreement with Harvard University 20

Vir Biotechnology and Harvard University Enter into Research Agreement 21

Elysium Health Enters into Research Agreement with Harvard University 22

Thrive Bioscience and Harvard Stem Cell Institute Enter into Agreement 23

Boehringer Ingelheim Enters into Research Agreement with Harvard Stem Cell Institute 24

Kiromic Enters into Agreement with Harvard Medical School 25

ConSynance Therapeutics Enters into Research Agreement with Harvard Medical School 26

Medgenics Enters into Agreement with Harvard University 27

Ipsen Enters into Research Agreement with Harvard University 28

AstraZeneca Enters into Research Agreement with Harvard Stem Cell Institute 29

Imcare Biotech Enters into Partnership with Harvard Medical School 30

Astellas Pharma Enters into Research Agreement with Harvard Medical School 31

Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 32

Evotec Enters Into Research Agreement With Harvard University For Enteroendocrine Mechanisms 33

Evotec Enters Into Research Agreement With Harvard Stem Cell Institute For Amyotrophic Lateral Sclerosis 34

Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 35

Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 36

Evotec Enters Into Research Agreement With Harvard University To Develop Antibacterial Drugs 37

Emory University And Children's Hospital of Philadelphia Enter Into Co-Development Agreement With Harvard University 38

UCB Enters Into R&D Agreement With Harvard University To Develop Immunology Drugs 39

Pfizer Enters Into Co-Development Agreement With Harvard University 40

UCB Enters Into Co-Development Agreement With Harvard University 41

Evotec Enters Into Co-Development Agreement With Harvard University And BWH 42

Licensing Agreements 44

Elysium Health Enters into Licensing Agreement with Mayo Clinic and Harvard University 44

Symbiotix Biotherapies Enters into Licensing Agreement with Harvard University 45

Novartis Enters into Licensing Agreement with SEAS, Wyss Institute for Biologically Inspired Engineering, Dana-Farber Cancer Institute and University of Michigan 46

Mustang Bio Enters into Licensing Agreement with Harvard University 47

X-Biotix Therapeutics Enters into Licensing Agreement with Harvard Medical School 48

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo 49

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, Massachusetts Institute of Technology and University of Iowa 51

Nobilis Therapeutics Enters into Licensing Agreement with Harvard University 53

Merck Enters into Licensing Agreement with Harvard University 54

Mesoblast Enters into Licensing Agreement with Harvard Medical School 55

Frequency Therapeutics Receives Intellectual Property Rights from MIT and Harvard Medical School 56

Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 57

Columbia Labs Enters into Licensing Agreement for IVR Technology 59

Macrolide Pharma Enters into Licensing Agreement with Harvard University Office of Technology Development 60

H&P Labs Enters into Licensing Agreement with Harvard University and Brigham and Women's Hospital 61

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, and Massachusetts Institute of Technology 62

SciFluor Life Sciences Extends Licensing Agreement With Harvard University For PET Imaging 64

Semma Therapeutics Enters into Licensing Agreement with Harvard University 65

Allied-Bristol Life Sciences Enters into Licensing Agreement with Harvard University 66

Horizon Discovery Enters Into Licensing Agreement With Harvard University For Crispr Gene Editing Technology 67

GNS Healthcare Enters Into Licensing Agreement With Harvard Medical School 68

TissueNetix Enters Into Licensing Agreement With Harvard University For Muscular Thin Film Technology 69

Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 70

Insero Health Enters Into Patent Licensing Agreement With Harvard University 72

Harvard University-Key Competitors 73

Harvard University-Key Employees 74

Harvard University-Locations And Subsidiaries 75

Head Office 75

Other Locations & Subsidiaries 75

Recent Developments 77

Legal and Regulatory 77

Sep 10, 2018: CRISPR Therapeutics, Intellia Therapeutics & Caribou Biosciences provide update on US federal circuit decision upholding the ruling by US patent and trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology 77

Government and Public Interest 78

Aug 29, 2018: New therapy spurs nerve fibers to regrow through scar tissue, transmit signals after spinal cord injury in rodents 78

Aug 20, 2018: Taking the brain apart to put it all together again 80

Jul 18, 2018: St. Baldrick's foundation announces USD 19.1 million in grants to fund lifesaving childhood cancer research 82

Apr 04, 2018: Hearing loss study at USC, Harvard shows hope for millions 83

Mar 19, 2018: Metastatic Prostate Cancer Project Explores a New Approach to Genomics Research 84

Mar 12, 2018: Switch that could improve memory identified 86

Mar 05, 2018: Personal cancer vaccines get their own boost 87

Dec 27, 2017: Technical University of Munich: Double strike against tuberculosis 89

Dec 20, 2017: CRISPR therapy preserves hearing in progressive deafness model 90

Nov 16, 2017: Study shows codeine prescribed to children despite FDA warning against it 92

Feb 10, 2017: U.S. Scientists Receive Inaugural USD 87 Million Grand Challenge Awards To Accelerate Global Progress To Beat Cancer Sooner 93

Product News 94

Nov 29, 2017: Innovative Microscope Poised to Propel Optogenetics Studies 94

Aug 20, 2018: NCI-led research team develops predictor for immunotherapy response in melanoma 96

Jun 27, 2018: New approach may eliminate daily injections for diabetics 97

Other Significant Developments 98

Jun 13, 2018: Researchers can count on improved proteomics method 98

Jun 05, 2018: Organ-on-Chip: a Growing MedTech Market Opportunity for Sensera MEMs 99

Appendix 100

Methodology 100

About GlobalData 100

Contact Us 100

Disclaimer 100


List of Figure

List of Figures

Harvard University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Harvard University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Harvard University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Harvard University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Harvard University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Harvard University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Harvard University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Harvard University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Harvard University, Medical Devices Deals, 2012 to YTD 2018 12


List of Table

List of Tables

Harvard University, Pharmaceuticals & Healthcare, Key Facts 2

Harvard University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Harvard University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Harvard University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Harvard University, Deals By Therapy Area, 2012 to YTD 2018 10

Harvard University, Medical Devices Deals, 2012 to YTD 2018 12

Harvard University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Beam Therapeutics Enters into Licensing Agreement with Harvard University 17

Bristol-Myers Squibb Enters into Research Agreement with Harvard Stem Cell Institute 18

Frequency Therapeutics Enters into Agreement with Harvard University and US Army Institute of Surgical Research 19

Les Laboratoires Servier Enters into Agreement with Harvard University 20

Vir Biotechnology and Harvard University Enter into Research Agreement 21

Elysium Health Enters into Research Agreement with Harvard University 22

Thrive Bioscience and Harvard Stem Cell Institute Enter into Agreement 23

Boehringer Ingelheim Enters into Research Agreement with Harvard Stem Cell Institute 24

Kiromic Enters into Agreement with Harvard Medical School 25

ConSynance Therapeutics Enters into Research Agreement with Harvard Medical School 26

Medgenics Enters into Agreement with Harvard University 27

Ipsen Enters into Research Agreement with Harvard University 28

AstraZeneca Enters into Research Agreement with Harvard Stem Cell Institute 29

Imcare Biotech Enters into Partnership with Harvard Medical School 30

Astellas Pharma Enters into Research Agreement with Harvard Medical School 31

Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 32

Evotec Enters Into Research Agreement With Harvard University For Enteroendocrine Mechanisms 33

Evotec Enters Into Research Agreement With Harvard Stem Cell Institute For Amyotrophic Lateral Sclerosis 34

Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 35

Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 36

Evotec Enters Into Research Agreement With Harvard University To Develop Antibacterial Drugs 37

Emory University And Children's Hospital of Philadelphia Enter Into Co-Development Agreement With Harvard University 38

UCB Enters Into R&D Agreement With Harvard University To Develop Immunology Drugs 39

Pfizer Enters Into Co-Development Agreement With Harvard University 40

UCB Enters Into Co-Development Agreement With Harvard University 41

Evotec Enters Into Co-Development Agreement With Harvard University And BWH 42

Elysium Health Enters into Licensing Agreement with Mayo Clinic and Harvard University 44

Symbiotix Biotherapies Enters into Licensing Agreement with Harvard University 45

Novartis Enters into Licensing Agreement with SEAS, Wyss Institute for Biologically Inspired Engineering, Dana-Farber Cancer Institute and University of Michigan 46

Mustang Bio Enters into Licensing Agreement with Harvard University 47

X-Biotix Therapeutics Enters into Licensing Agreement with Harvard Medical School 48

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo 49

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, Massachusetts Institute of Technology and University of Iowa 51

Nobilis Therapeutics Enters into Licensing Agreement with Harvard University 53

Merck Enters into Licensing Agreement with Harvard University 54

Mesoblast Enters into Licensing Agreement with Harvard Medical School 55

Frequency Therapeutics Receives Intellectual Property Rights from MIT and Harvard Medical School 56

Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 57

Columbia Labs Enters into Licensing Agreement for IVR Technology 59

Macrolide Pharma Enters into Licensing Agreement with Harvard University Office of Technology Development 60

H&P Labs Enters into Licensing Agreement with Harvard University and Brigham and Women's Hospital 61

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, and Massachusetts Institute of Technology 62

SciFluor Life Sciences Extends Licensing Agreement With Harvard University For PET Imaging 64

Semma Therapeutics Enters into Licensing Agreement with Harvard University 65

Allied-Bristol Life Sciences Enters into Licensing Agreement with Harvard University 66

Horizon Discovery Enters Into Licensing Agreement With Harvard University For Crispr Gene Editing Technology 67

GNS Healthcare Enters Into Licensing Agreement With Harvard Medical School 68

TissueNetix Enters Into Licensing Agreement With Harvard University For Muscular Thin Film Technology 69

Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 70

Insero Health Enters Into Patent Licensing Agreement With Harvard University 72

Harvard University, Key Competitors 73

Harvard University, Key Employees 74

Harvard University, Other Locations 75

Harvard University, Subsidiaries 75

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022